scPharmaceuticals receives five Notices of Allowance for SCP-111 formulation patents.

scPharmaceuticals Inc. has received five Notices of Allowance from the USPTO for patent applications covering its furosemide formulation, SCP-111. This strengthens the company's patent protection and supports the filing of a supplemental NDA for SCP-111, which is expected this quarter. The formulation aims to provide effective care for patients with edema due to heart failure or chronic kidney disease.

scPharmaceuticals Inc. (SCPH) has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering its latest furosemide formulation, SCP-111. This development strengthens the company's intellectual property portfolio and supports the filing of a supplemental New Drug Application (NDA) for SCP-111, which is expected this quarter. The patented formulation aims to provide effective care for patients with edema due to heart failure or chronic kidney disease.

The five patents, once issued, will join four additional patents owned by the company that cover the SCP-111 formulation. John Tucker, Chief Executive Officer of scPharmaceuticals, commented, "These allowances are vital developments in scPharmaceuticals’ pursuit to provide effective care to patients suffering from edema due to heart failure or chronic kidney disease. Securing additional patent protection represents a key strategic achievement that strengthens the Company’s intellectual property portfolio, which I believe supports the advancement of next-generation formulations and reinforces our commitment to delivering transformative outcomes for patients while expanding market opportunities."

The company's latest patent portfolio expansion comes as scPharmaceuticals continues to build momentum in the pharmaceutical sector. In the second quarter of 2025, the company generated $16 million in net revenue, a 99% increase over the same period in 2024. This growth was driven by the launch of FUROSCIX into the nephrology market, which saw faster adoption among nephrologists compared to cardiologists. The company's commercial strategy for FUROSCIX, including the upcoming proposal of an ambulatory specialty model (ASM) by CMS, is expected to further boost its market penetration.

scPharmaceuticals remains focused on its long-term growth strategy, with a particular emphasis on nephrology. The company's CEO, John Tucker, highlighted the potential for nephrology to contribute significantly to the company's third-quarter results, noting that the market's faster adoption and positive trends in Part D dynamics could drive substantial growth.

The company's financial results for the second quarter of 2025 reflect its ongoing efforts to expand its market reach and improve patient outcomes. Product revenues for the quarter were $16 million, up from $11.8 million in the first quarter of 2025. Cost of product revenues rose to $5 million from $3.5 million in Q1, with a gross to net discount of approximately 27%. Cash and cash equivalents ended the quarter at $40.8 million, a decrease from $57.5 million at the end of Q1 2025, reflecting the company's continued investment in its product development and commercialization efforts.

In conclusion, scPharmaceuticals Inc. has made significant strides in strengthening its intellectual property portfolio and expanding its market reach. With the recent patent allowances and the anticipated filing of a supplemental NDA for SCP-111, the company is well-positioned to continue delivering innovative solutions for patients with edema due to heart failure or chronic kidney disease.

References:
[1] https://www.stocktitan.net/news/SCPH/sc-pharmaceuticals-receives-notice-of-allowances-of-multiple-us-ot0ljaegfmlo.html
[2] https://seekingalpha.com/news/4482806-scpharmaceuticals-anticipates-meaningful-q3-nephrology-contribution-as-furoscix-shipments